Charles DeBattista
Academic Appointments
- Professor - Med Center Line, Psychiatry & Behavioral Science - Psychopharmacology
Key Documents
Contact Information
-
Clinical Offices
Psychiatry Department 401 Quarry Rd MC 5723 Stanford, CA 94305 Tel Work (650) 723-8335 Fax (650) 724-9900
- Academic Offices
Personal Information Email Tel (650) 723-8324Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Psychiatry
- Clinical Psychopharmacology
- Resistant Depression
- Neuromodulation
Honors and Awards
- America's Best Doctors; Psychiatry, Best Doctors (2009-2010)
- Review Article of the Year, Primary Psychiatry (2004)
- Teacher of the Year, Dept. Of Psychiatry (1998, 2000, 2001)
Professional Education
| Board Certification: | Psychiatry, American Board of Psychiatry and Neurology (1995) |
| Fellowship: | Stanford University Medical Center CA (1993) |
| Medical Education: | UCSF School of Medicine CA (1989) |
| DMH: | UCSF/UC Berkeley, Mental Health (1986) |
| MD: | UCSF, Medicine (1989) |
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Treatment resistant depression.
Novel biological interventions in the treatment of mental illness.
Anti-glucocorticoid drugs in the treatment of mood disorders.
Augmentation strategies in the treatment of depression.
Clinical Trials
- Recruiting International Study to Predict Optimised Treatment - in Depression
- Not Recruiting 24-Week Placebo-Controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
- Recruiting Treatment Trial for Psychogenic Nonepileptic Seizures
- Not Recruiting Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression
- Recruiting Radiosurgical Neuromodulation for Refractory Depression
Publications
- Measuring severe adverse events and medication selection using a "PEER Report" for nonpsychotic patients: a retrospective chart review. Neuropsychiatr Dis Treat. 2012: 277-84
- The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. J Psychiatr Res. 2011; (1): 64-75
- Response to Dr. Tsai's letter to the Editor - The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. J Psychiatr Res. 2010
- Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects. Curr Drug Saf. 2010; (3): 263-6
- A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. Contemp Clin Trials. 2009; (4): 284-8
- Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function. Psychoneuroendocrinology. 2009; (7): 1012-8
Help
Trial Administration